In Response: Letter Received From Dr. Charles Ricordel Titled “Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC”
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference5 articles.
1. Safety implications of switching pembrolizumab dosage from 200 mg every 3 weeks to 400 mg every 6 weeks in patients with advanced NSCLC;Higashiyama;J Thorac Oncol,2022
2. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation;Lala;Eur J Cancer,2020
3. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer;Long;Ann Oncol,2018
4. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis;Xu;BMJ,2018
5. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: a population pharmacokinetic analysis in real-world non-small cell lung cancer patients;Ohuchi;Lung Cancer,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3